461 related articles for article (PubMed ID: 10096369)
1. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
2. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
Roehrborn CG; McConnell JD; Saltzman B; Bergner D; Gray T; Narayan P; Cook TJ; Johnson-Levonas AO; Quezada WA; Waldstreicher J;
Eur Urol; 2002 Jul; 42(1):1-6. PubMed ID: 12121721
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
[TBL] [Abstract][Full Text] [Related]
4. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.
Marberger MJ; Andersen JT; Nickel JC; Malice MP; Gabriel M; Pappas F; Meehan A; Stoner E; Waldstreicher J
Eur Urol; 2000 Nov; 38(5):563-8. PubMed ID: 11096237
[TBL] [Abstract][Full Text] [Related]
5. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
Roehrborn CG; Bruskewitz R; Nickel GC; Glickman S; Cox C; Anderson R; Kandzari S; Herlihy R; Kornitzer G; Brown BT; Holtgrewe HL; Taylor A; Wang D; Waldstreicher J
Eur Urol; 2000 May; 37(5):528-36. PubMed ID: 10765090
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
7. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
8. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
[TBL] [Abstract][Full Text] [Related]
9. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
11. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.
Roehrborn CG
Urology; 2002 Jun; 59(6):811-5. PubMed ID: 12031358
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG
Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.
Roehrborn CG; Malice M; Cook TJ; Girman CJ
Urology; 2001 Aug; 58(2):210-6. PubMed ID: 11489703
[TBL] [Abstract][Full Text] [Related]
15. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.
Andersen JT; Nickel JC; Marshall VR; Schulman CC; Boyle P
Urology; 1997 Jun; 49(6):839-45. PubMed ID: 9187688
[TBL] [Abstract][Full Text] [Related]
16. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
17. [Serum PSA and transition zone index as predictors of acute urinary retention in benign prostate hyperplasia].
Zhu S; Chen S; Li Q; Lin Z; Zheng S; Weng M
Zhonghua Nan Ke Xue; 2004 Jan; 10(1):24-5. PubMed ID: 14979202
[TBL] [Abstract][Full Text] [Related]
18. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
19. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
20. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
